renin-angiotensin system
Stephen B Harrap From its origins in renal physiology, the reninangiotensin system has established its functional and pathological significance for many organs. For cardiovascular tissues, both circulating and tissue components of this system appear to be relevant. Changes in its activity have been associated with important effects on the normal and diseased circulation.1 2 Therapeutic interference with the system is of proven benefit in hypertension, cardiac hypertrophy, following myocardial infarction, and in heart failure.3-5 Therefore it is not surprising that genes associated with the reninangiotensin system are popular candidates for the investigation. siderable activity (figure). Clear answers have not yet crystallised and the task is far from simple.8
THE RENIN GENE
A logical contender for hypertension since the Goldblatt era, the renin gene was among the first genes to be cloned. However, available markers of the gene have not been linked with cardiovascular disease9 11 and interest has waned. Nevertheless, existing renin gene markers probably reflect a small amount of the individual variation in DNA in and around this gene. An important role for the renin gene cannot be discounted and new informative markers may rekindle interest.
Genetics of the renin-angiotensin system
The discovery of the genes that encode renin, angiotensinogen, angiotensin converting enzyme (ACE), and angiotensin receptors has made genetic analysis a reality. Certain molecular markers reveal genetic variation between individuals which, in the case of angiotensinogen and ACE genes, are associated with significant differences in the activity of the renin-angiotensin system. These functional correlations may be relevant to normal physiological variation or cardiovascular disease, particularly where familial predisposition is evident.
Molecular Whether genetic or environmental, if population differences explain the observed inconsistencies, it is unwise to extrapolate the results from one community to another unless there is some evidence of uniformity across different groups. POPULATION 
SAMPLING
To demonstrate linkage between a genetic marker (and the surrounding stretches of chromosome) and cardiovascular disease, it is necessary to study inheritance in families. Traditional multigenerational pedigree studies are difficult for conditions such as myocardial infarction which do not declare themselves until later in life. New methods using affected pairs of relatives are gaining favour but demand considerable expertise, time, and resources.
The most convenient sampling is the casecontrol study in which the frequency of a particular genetic marker is compared between two groups. Although not a strict test of inheritance, case-control studies are the ultimate test of the usefulness of genetic markers in the broader community.50 The statistical association between a marker and disease often rests on relatively small differences in the proportion of cases and controls with the marker. But statistical significance does not necessarily equate with biological significance. Uncontrolled influences of racial or environmental factors may cause significant bias. Spurious differences may be created and important differences obscured unless particular care is taken in sampling. It is not justifiable, either scientifically or ethically, to use blood stored for some other purpose as "control data".
Case-control studies have other limitations. For example, findings in 55 year old survivors of myocardial infarction tell us nothing about those who did not make it. As an explanation of increased numbers of myocardial infarction survivors with the ACE DD genotype,30 it is plausible that individuals with the ACE II genotype are predisposed to sudden death following coronary occlusion, artificially inflating the proportion of surviving cases with the DD genotype. Alternatively, the DD genotype might provide a non-specific protective effect against death rather than predisposition to ischaemic heart disease. The increased prevalence of the DD genotype in centenarians might support such a hypothesis.51 These possibilities are not discernable in cross sectional studies and require prospective research.
PHENOTYPE CHARACTERISATION
Inconsistency in genetic analysis may arise unless phenotypes are comparable. Phenotypes should be clinically relevant and measurable using standard criteria. For example, we cannot assume that all manifestations of coronary artery disease are the same. Atherosclerotic luminal narrowing on coronary angiography may not share the same genetic origins as myocardial infarction, which involves an interaction between thrombosis and atherosclerosis. The genetics of sudden coronary death may not mirror those of uncomplicated myocardial infarction. Genes associated with very high blood pressure'3 may not necessarily be relevant to the more common clinical conditions of mild or moderate hypertension. Cardiac hypertrophy on electrocardiography35 defines a different group to that based on echocardiography.4 SUBGROUP ANALYSIS Given the phenotypic diversity, do subgroups exist in which more precise genetic links can be defined? In the first study of the ACE gene and myocardial infarction,30 cases and controls were separated by body mass index, apolipoprotein B, and lipid lowering therapy into "high" and "low" coronary risk groups. The association between the DD genotype and myocardial infarction existed only in the low group.30 That the DD genotype should be detrimental only in the absence of other risk factors is unusual. 52 The significance of this finding is also uncertain because the idiosyncratic "high/low" definition resulted in 74% of the controls categorised as "high" risk.
Subgrouping has also been based on molecular analysis. The combination of the DD genotype of the ACE gene and the C variant of the angiotensin type 1 receptor gene (AT,/C) appeared to be more closely associated with myocardial infarction than either variant alone, although the AT,/C was not itself associated with myocardial infarction. 44 Attempts to define subgroups are understandable, but a note of caution is required. Unless subgroups are postulated a priori, their discovery may owe more to random variation than biology and only serves to generate rather than test hypotheses. Furthermore, subgrouping may be a case of diminishing returns. To be useful, genetic markers must not be so rare that screening becomes inefficient, nor so common that they are found in most people. Of 613 cases of myocardial infarction,30 the highlighted combinations of the ACE/DD genotype with "low" risk, and the ACE/DD genotype with the ATI/C genotype comprised only 6% and 2% of cases respectively.3044 The combination of the ACE/DD genotype and at least one C allele of the AT, gene was slightly more common, present in 18% of cases. However, it was also found in 13% of controls. As controls are at least twice as common as cases, a study of the general community would find this genetic duo more frequently associated with controls than cases. Such a combination would not really assist the practising physician to predict coronary risk. The expectations raised by terms such as "potent" risk factor do not seem to be justified.30 GENETIC 
MARKERS
It is easy to overlook the fact that molecular markers of the ACE, angiotensinogen, and angiotensin receptor genes are simply flags on the respective chromosomes. Disease mutations may be some distance from markers, even in adjacent genes that serve quite different functions independent of the reninangiotensin system. The ability to resolve the fine molecular details and pinpoint disease mutations is often very difficult. There is a need to complement the molecular approach to define the biochemical and physiological steps involving the renin-angiotensin system between DNA and disease. 27 This not only strengthens the genetic case, but also provides new strategies for prevention and treatment.
PUBLICATION BIAS
It is not difficult to understand the reluctance of editors to publish negative studies. Because five out of 100 studies will produce a "statistically significant" result by chance alone, we must also foster the publication of studies that test rather than generate genetic hypotheses. Reproducibility both within and between populations has critical implications for our future practice. 
Conclusion

